Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MST-997
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MST-997 is an antibody-drug conjugate (ADC) that was developed by Wyeth (now a wholly owned subsidiary of Pfizer) for the treatment of advanced malignant solid tumors, including metastatic breast cancer and non-small cell lung cancer. The agent consists of a humanized monoclonal antibody (huHMFG1) targeting Mucin 1 (MUC1), a cell surface glycoprotein that is frequently overexpressed and aberrantly glycosylated in various epithelial malignancies. The antibody is conjugated to the cytotoxic maytansinoid derivative DM1 (mertansine), a potent microtubule inhibitor. Upon binding to MUC1 on the surface of cancer cells and subsequent internalization, the DM1 payload is released, leading to cell cycle arrest in the G2/M phase and apoptosis. Clinical development reached Phase 1 clinical trials (NCT00094133) but was subsequently discontinued.
- Other names
- huHMFG1-DM1huHMFG-1-DM1huHMFG 1-DM1
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on MST-997.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MST-997.